GlassScriptPhysician profile
William R Bartley
NPI 1134112097
$2,659.96
in general payments reported to CMS, 2019-2025
24 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $142 · 2021: $278 · 2022: $307 · 2023: $85.71 · 2024: $457 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.67 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $847.42 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $439.01 | 2019-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $265.85 | 2019-2025 | |
| Abbott Laboratories | $186.14 | 2019 | |
| Novo Nordisk INC | $169.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $158.55 | 2019-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $96.06 | 2019 | |
| Glaxosmithkline, LLC. | $70.94 | 2021 | |
| Daiichi Sankyo INC. | $65.56 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $52.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.25 | 2019-2020 | |
| Abbvie INC. | $35.17 | 2024 | |
| Pfizer INC. | $30.46 | 2024 | |
| Exact Sciences Corporation | $28.18 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $23.75 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.51 | 2019 | |
| Almatica Pharma LLC | $20.00 | 2025 | Teriparatide, Loreev Xr |
| Sanofi-Aventis U.S. LLC | $20.00 | 2021 | |
| Amgen INC. | $15.54 | 2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.98 | 2023 | Xifaxan |
| Amarin Pharma, INC. | $14.22 | 2020 | |
| Duchesnay USA Incorporated | $13.83 | 2019 | |
| Apria Healthcare LLC | $13.18 | 2021 | |
| Ge Healthcare | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bartley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.